Effect of sample size and the traditional parametric, nonparametric, and robust methods on the establishment of reference intervals: Evidence from real world data

Author(s):  
Chaochao Ma ◽  
Xinlu Wang ◽  
Liangyu Xia ◽  
Xinqi Cheng ◽  
Ling Qiu
2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tatjana Ammer ◽  
André Schützenmeister ◽  
Hans-Ulrich Prokosch ◽  
Manfred Rauh ◽  
Christopher M. Rank ◽  
...  

AbstractReference intervals are essential for the interpretation of laboratory test results in medicine. We propose a novel indirect approach to estimate reference intervals from real-world data as an alternative to direct methods, which require samples from healthy individuals. The presented refineR algorithm separates the non-pathological distribution from the pathological distribution of observed test results using an inverse approach and identifies the model that best explains the non-pathological distribution. To evaluate its performance, we simulated test results from six common laboratory analytes with a varying location and fraction of pathological test results. Estimated reference intervals were compared to the ground truth, an alternative indirect method (kosmic), and the direct method (N = 120 and N = 400 samples). Overall, refineR achieved the lowest mean percentage error of all methods (2.77%). Analyzing the amount of reference intervals within ± 1 total error deviation from the ground truth, refineR (82.5%) was inferior to the direct method with N = 400 samples (90.1%), but outperformed kosmic (70.8%) and the direct method with N = 120 (67.4%). Additionally, reference intervals estimated from pediatric data were comparable to published direct method studies. In conclusion, the refineR algorithm enables precise estimation of reference intervals from real-world data and represents a viable complement to the direct method.


2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Lei Huang ◽  
Liwen Su ◽  
Yuling Zheng ◽  
Yuanyuan Chen ◽  
Fangrong Yan

Abstract Recently, real-world study has attracted wide attention for drug development. In bioequivalence study, the reference drug often has been marketed for many years and accumulated abundant real-world data. It is therefore appealing to incorporate these data in the design to improve trial efficiency. In this paper, we propose a Bayesian method to include real-world data of the reference drug in a current bioequivalence trial, with the aim to increase the power of analysis and reduce sample size for long half-life drugs. We adopt the power prior method for incorporating real-world data and use the average bioequivalence posterior probability to evaluate the bioequivalence between the test drug and the reference drug. Simulations were conducted to investigate the performance of the proposed method in different scenarios. The simulation results show that the proposed design has higher power than the traditional design without borrowing real-world data, while controlling the type I error. Moreover, the proposed method saves sample size and reduces costs for the trial.


2016 ◽  
Vol 22 ◽  
pp. 219
Author(s):  
Roberto Salvatori ◽  
Olga Gambetti ◽  
Whitney Woodmansee ◽  
David Cox ◽  
Beloo Mirakhur ◽  
...  

2020 ◽  
Author(s):  
Jersy Cardenas ◽  
Gomez Nancy Sanchez ◽  
Sierra Poyatos Roberto Miguel ◽  
Luca Bogdana Luiza ◽  
Mostoles Naiara Modroño ◽  
...  

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 209-OR
Author(s):  
SHWETA GOPALAKRISHNAN ◽  
PRATIK AGRAWAL ◽  
MICHAEL STONE ◽  
CATHERINE FOGEL ◽  
SCOTT W. LEE

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 994-P
Author(s):  
PRATIK AGRAWAL ◽  
MICHAEL STONE ◽  
SHWETA GOPALAKRISHNAN ◽  
CATHERINE FOGEL ◽  
SCOTT W. LEE ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document